Corporate Overview Jefferies 2019 Healthcare Conference - June 7, 2019
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Corporate Overview Jefferies 2019 Healthcare Conference June 7, 2019 Nasdaq: ANAB
Safe Harbor Statement
This presentation and the accompanying oral presentation contain “forward‐looking” statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of
data from our clinical trials, including etokimab’s Phase 2b clinical trial in moderate-to-severe adult atopic dermatitis patients,
etokimab’s Phase 2 clinical trial in adult chronic rhinosinusitis with nasal polyps patients and ANB019’s Phase 2 trials in GPP and PPP
patients; the design of and our ability to launch a Phase 2b clinical trial of etokimab in eosinophilic asthma patients; the timing of an
IND filing for ANB030, our new wholly-owned anti-inflammatory antibody program; the timing of a BLA filing for TESARO’s
dostarlimab product candidate; and the milestones and success of our partnerships with TESARO (recently acquired by
GlaxoSmithKline) and Celgene. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the
future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as
assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those
expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that
may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement,
including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of
and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to
fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks
and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities
and Exchange Commission. These forward-looking statements speak only as of the date of this presentation, and the company
undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date
hereof.
Certain information contained in this presentation may be derived from information provided by industry sources. The Company
believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company
cannot guarantee the accuracy of, and has not independently verified, such information.
The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should
not be construed as an endorsement of such products.
2
AnaptysBio: Clinical-Stage Antibody Development Company
Focused on Novel Antibody Medicines for Severe Inflammatory Diseases
Wholly-Owned Rapid Antibody Generation
Anti-Inflammatory Pipeline Platform Technology
Etokimab (ANB020, Anti-IL-33)
Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinusitis with Nasal Polyps Antibody Preclinical & IND or
Discovery Translational Equivalent Filing
ANB019 (Anti-IL-36R)
Generalized Pustular Psoriasis & Palmoplantar Pustulosis
~2.5 years
ANB030 (PD-1 Agonist)
Inflammatory Diseases
Antibody Medicines
For Severe Diseases
Multiple Efficacy Readouts Anticipated
Validating Product Partnerships From Wholly-Owned Pipeline
Generated ~$80MM*
ANB019 Generalized Pustular Psoriasis Phase 2: Top-line data
in mid 2019
TESARO Etokimab Atopic Dermatitis Phase 2b: Top-line data in H2 2019
Etokimab Chronic Rhinosinusitis With Nasal Polyps Phase 2:
Celgene Top-line data in H2 2019
ANB019 Palmoplantar Pustulosis Phase 2: Top-line data in H1
2020
* As of March 31st 2019
3
Wholly-Owned and Partnered Product Pipeline
6 AnaptysBio-Generated Antibodies Advanced to Clinic Since Q1 2016
Development Stage & Anticipated Milestones
Program Therapeutic Indication Commercial Rights
Discovery Preclinical Phase 1 Phase 2 Phase 3
Phase 2a Data Presented at ATLAS: Phase 2b Top-Line
Atopic Dermatitis
AAD and EAACI 2018 Data H2 2019
Etokimab (ANB020): Phase 1 Data Presented at Phase 2a Data Presented at Phase 2b To Be Initiated in
Eosinophilic Asthma
Anti-IL-33 AAD and AAAAI 2017 EAACI 2019 2019
Chronic Rhinosinusitis With ECLIPSE: Phase 2 Top-Line Data
Nasal Polyps H2 2019
Generalized Pustular GALLOP: Phase 2 Top-Line Data
Psoriasis Mid 2019
Phase 1 Data Presented
ANB019: Anti-IL-36R
at EAACI 2018
POPLAR: Phase 2 Top-Line Data
Palmoplantar Pustulosis
H1 2020
ANB030: Anti-PD-1
Inflammatory Diseases IND Filing H2 2019
Agonist
Dostarlimab (TSR-042):
Immuno-Oncology BLA Filing Anticipated in H2 2019
Anti-PD-1
TSR-022: Anti-TIM-3 Immuno-Oncology TSR-042 Combination Trial Ongoing
TSR-042 Combination Trial
TSR-033: Anti-LAG-3 Immuno-Oncology
Ongoing
TSR-075: Anti-PD-1/ IND-Enabling Studies
Immuno-Oncology
LAG-3 Bispecific Ongoing
CC-90006: Anti-PD-1
Psoriasis Ongoing
Agonist
Undisclosed Inflammation Ongoing
All programs generated internally using AnaptysBio’s proprietary antibody generation platform technology
4
Wholly-Owned Pipeline: Etokimab (ANB020, Anti-IL-33) Moderate-to-Severe Atopic Dermatitis Moderate-to-Severe Eosinophilic Asthma Chronic Rhinosinusitis with Nasal Polyps
Atopic Diseases: Large Unmet Medical Need
IL-33-driven Disease Mechanism Affects Multiple Organ Systems
Atopic Dermatitis
Skin • 1.4 million adult atopic dermatitis patients in the US
• Estimate ~280,000 adults with moderate-to-severe atopic dermatitis
Eosinophilic Asthma
Lung • 19 million adult patients diagnosed with asthma in the US
Inflammatory
• Estimate ~1.1M adults with severe asthma insufficiently controlled
Response to through standard-of-care
Allergen
Chronic Rhinosinusitis with Nasal Polyps
Sinus
• 1.3 million adults diagnosed in the US
• Estimate ~400,000 adults inadequately controlled with standard-of-care
Atopic diseases occur through a common inflammatory response to an allergen, leading
to concomitant incidence of multiple atopic diseases amongst some patients
6
Etokimab: First-in-Class Anti-IL-33 Antibody
Broadly Applicable to Atopic Diseases
• IL-33 is an upstream driver of
atopic disease
– Human genetics validate key role of IL-33 in
atopic dermatitis and asthma
– Pro-inflammatory cytokine released upon
allergen contact with epithelium
– Activates downstream release of IL-4, IL-5
and IL-13
– Modulates IgE-mediated mast cell and
basophil degranulation
• Etokimab is a potentially first-in-
class anti-IL-33 cytokine
antibody
– Phase I healthy volunteer trial completed
without dose-limiting toxicities IL-33 acts as a gatekeeper of allergic response with demonstrated
– AnaptysBio pursuing development in activity in the initiation (activation of ILC2 cells)1, propagation (activation
moderate-to-severe atopic dermatitis, of allergen-specific T and B cells)2 and amplification (degranulation of
moderate-to-severe eosinophilic asthma mast cells and basophils)3.
and chronic rhinosinusitis with nasal polyps
1. Cayrol et al. Curr Opin Immunol (2014) 31:31
2. Peine et al. Trends Immunol (2016) 37(5):321
3. Saluja et al. Clin Transl Allergy (2015) 5:33
7
Etokimab Atopic Dermatitis Phase 2a Clinical Trial
Single Dose of Etokimab Administered on Day 1
Day 113
Day 140
Day -21
Day 78
Day 15
Day 29
Day 57
Day -7
Day 1
Enrollment
Placebo Etokimab
n=12
IV Single Dose 300mg IV Single Dose
Patient Adult Moderate-to-Severe Atopic Dermatitis Patients
Population Average baseline EASI score of 32
Clinical: EASI, 5-D pruritus, SCORAD, IGA, DLQI, safety
Key Endpoints Biomarkers: Circulating eosinophils, ex-vivo IFN-g PD, granulocyte skin infiltration
8
EASI Scores Following Single Etokimab Dose
Rapid Response & All Patients Achieved EASI-50 On Or Before Day 57
90% % Patients Achieving EASI-50
% Patients Achieving EASI-75 Average % Patients % Patients
Average % EASI Score Reduction Timepoint % EASI Score Achieving Achieving
80% Reduction* EASI-50* EASI-75*
Day -21
0% 0 0
70% (Baseline)
Day 1
4% 0 0
60% (Etokimab Dosing)
9 of 12 3 of 12
Day 15 58%
50% (75%) (25%)
10 of 12 4 of 12
Day 29 61%
40% (83%) (33%)
9 of 12 5 of 12
Day 57 62%
30% (75%) (42%)
9 of 12 2 of 12
Day 78 62%
20% (75%) (17%)
8 of 12 2 of 12
Day 113 55%
10% (67%) (17%)
5 of 12 3 of 12
Day 140 45%
0% (42%) (25%)
Day -21 Day 1 Day 15 Day 29 Day 57 Day 78 Day 113 Day 140
* Relative to baseline upon enrollment at Day -21
Time
9
Additional Efficacy Data
5-D Pruritus, SCORAD, DLQI and IGA Scores
60%
Average % 5-D Average % Average %
Timepoint Pruritus Score SCORAD DLQI
Reduction* Reduction* Reduction*
50%
Day -21
0% 0% 0%
(Baseline)
Day 1
40% (Etokimab 10% 3% 21%
Dosing)
Day 15 28% 37% 43%
30%
Percentage
Day 29 32% 40% 45%
20%
Day 57 21% 38% 48%
10%
Day 78 25% 40% 55%
0% Day 113 17% 38% 35%
Day -21 Day 1 Day 15 Day 29 Day 57 Day 78 Day 113 Day 140
Time
Average % 5-D Pruritus Score Reduction Average % SCORAD Reduction Day 140 21% 32% 43%
Average % DLQI Reduction
* Relative to baseline upon enrollment at Day -21
IGA scores of zero or 1 (clear/almost clear skin) observed in 25% (3/12) of patients
10Biomarker Data
Clinical Efficacy Consistent With Reduction of Blood Eosinophil Levels and Ex Vivo
Pharmacodynamic Assay
% Ex Vivo IL-33-
100% % Blood % Patients % Patients
Mediated IFN-g
Timepoint Eosinophil Achieving Achieving
Release
Reduction* EASI-50* EASI-75*
90% Reduction*
80% Day -21
0% 0% 0% 0%
(Baseline)
70%
Day 1-4** 25% 98% 0% 0%
60%
Percentage
50% Day 15 37% Not measured 75% 25%
40%
Day 29 40% Not measured 83% 33%
30%
Day 57 39% 86% 75% 42%
20%
Day 78 18% Not measured 75% 17%
10%
Day 113 Not measured 27% 67% 17%
0%
Day -21 Day 1-4 Day 15 Day 29 Day 57 Day 78 Day 113 Day 140
Day Day 140 16% 29% 42% 25%
% Patients Achieving EASI-50 % Patients Achieving EASI-75
% Eosinophil Reduction % Ex Vivo IFN-g Release Reduction * Average relative to baseline upon enrollment
** 6 to 72 hours post-etokimab dose
Etokimab-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies#
Inhibition of ex vivo IL-33-mediated interferon-gamma (IFN-g) release consistent with Phase 1 pharmacodynamic results
# Smith et al. (2017) A rare IL33 loss-of-function mutation reduces blood eosinophil counts and protects from asthma. PLoS Genet 13(3): e1006659.
11Etokimab Atopic Dermatitis Phase 2a Clinical Trial
Summary
• Rapid and persistent EASI score improvement following single dose of etokimab
- Rapid efficacy observed as early as Day 15
- Efficacy was maximized between Day 29 and Day 57
- All patients achieved at least EASI-50 response on or before Day 57
- EASI responses consistent with 5-D pruritus, SCORAD, DLQI and IGA scores
• Etokimab improved EASI scores irrespective of disease severity
- Etokimab showed similar improvement in the seven of 12 patients with higher baseline EASI scores (treated with systemic
immuno-modulators pre-study) versus the five of 12 patient with lower baseline EASI scores that did not require systemic
therapy pre-study
• Biomarker data consistent with etokimab EASI score improvement
- Etokimab-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33 loss-of-function studies
- Ex vivo IL-33-mediated IFN-g release consistent with Phase 1 pharmacodynamic assay results
• Etokimab was well-tolerated and no drug-related safety signals observed
- Most frequent adverse event was dizziness in 17% of patients post-placebo versus headache in 25% of patients post-
etokimab
- A single serious adverse event of depression reported on Day 140 post-etokimab, which was consistent with the patient’s
pre-trial history of depression, and was deemed not drug-related
12ATLAS: Etokimab Atopic Dermatitis Phase 2b Trial
Top-line Data Anticipated in H2 2019
Treatment Period Monitoring Period
Week 16
Week 24
Week 0
Etokimab 600mg SC Loading Dose +
300mg SC q4w Maintenance Dose
Etokimab 300mg SC Loading Dose +
Randomization
150mg SC q4w Maintenance Dose
n=300
Etokimab 300mg SC Loading Dose +
150mg SC q8w Maintenance Dose
Etokimab 20mg SC q4w Maintenance Dose
Placebo
Patient Moderate-to-Severe Adult Atopic Dermatitis
Population Baseline EASI ≥16, BSA ≥10%, IGA ≥3
Key Endpoints Primary: % change in EASI
Week 16 Secondary: EASI-50, EASI-75, IGA, SCORAD, Pruritus NRS, safety
ClinicalTrials.gov: NCT03533751
13Etokimab Eosinophilic Asthma Phase 2a Trial
Single Dose of Etokimab or Placebo Administered on Day 1
Day 1 (Baseline)
Day 127
Day 106
Day 36
Day 64
Day 85
Day 22
Day 8
Day 2
Randomization
Etokimab 300mg IV Single Dose + High Dose ICS/LABA n=12
n=25
Placebo Single Dose + High Dose ICS/LABA n=13
Adults with severe asthma (according to GINA 2016)
Pre-bronchodilator FEV1FEV1 Improvement Relative to Baseline After Single Dose
Rapid and Sustained Lung Function Improvement In Etokimab Arm
18%
FEV1 Improvement
Relative to Baseline
16% Timepoint
Etokimab Placebo Net
14%
Day 2 12% 4% 8%
12%
Day 8 9% 5% 4%
Improvement Relative to Baseline
10%
Day 22 16% 8% 8%
8%
Day 36 14% 8% 6%
6% Day 64 15% 4% 11%
4% Day 85 9% 7% 2%
2% Day 106 11% 11% 0%
0% Day 127 13% 8% 5%
12 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127
Day Etokimab Placebo
15ACQ-5 Score Reduction Relative to Baseline After Single Dose
Etokimab Arm Achieved Minimal Clinically Important Difference (MCID) of 0.50 Score
Reduction Relative to Baseline
-
ACQ-5 Score Reduction
Relative to Baseline
Timepoint
(0.10)
Etokimab Placebo Net
(0.20)
Day 8 -0.62 -0.09 -0.52
Reduction Relative to Baseline
(0.30)
Day 22 -0.48 -0.25 -0.24
(0.40)
Day 36 -0.60 -0.12 -0.48
(0.50) MCID
Day 64 -0.67 -0.12 -0.54
(0.60)
Day 85 -0.67 -0.18 -0.48
(0.70)
Day 106 -0.72 -0.44 -0.27
(0.80) Day 127 -0.77 -0.36 -0.41
1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127
Day Etokimab Placebo
16Blood Eosinophil Reduction Relative to Baseline After Single Dose
Consistent With Phase 2a Atopic Dermatitis Trial
20%
Blood Eosinophil Reduction
Relative to Baseline
Timepoint
10%
Etokimab Placebo Net
0% Day 2 -22% 9% -31%
Reduction Relative to Baseline
Day 8 -34% -15% -19%
-10%
Day 22 -30% -10% -20%
-20%
Day 36 -43% 1% -44%
-30% Day 64 -40% 6% -46%
Day 85 -36% -7% -29%
-40%
Day 106 -19% -13% -6%
-50%
12 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 Day 127 -24% -16% -8%
Day Etokimab Placebo
17Etokimab Eosinophilic Asthma Phase 2a Trial
Summary
• Single dose of etokimab resulted in rapid and sustained improvement in FEV1 and
ACQ-5 score reduction through at least Day 64
- Eosinophil reduction data consistent with prior atopic dermatitis Phase 2a trial
• Clinical trials to date support infrequent dosing of etokimab across atopic diseases
• Asthma exacerbations were observed post-Day 64 in one etokimab-dosed patient and
two placebo-dosed patients
- Rescue therapies, including short-acting beta agonist (SABA) and oral corticosteroids, were utilized in the
management of each exacerbation occurrence
• Etokimab was generally well-tolerated and no serious adverse events reported
- No treatment-emergent adverse events were deemed to be etokimab-related
- The most frequent treatment-emergent adverse events reported in the etokimab arm were moderate strep throat
in two patients
- Placebo-dosed patients reported the most frequent treatment-emergent adverse events as mild vomiting in two
patients, mild and moderate asthma exacerbations in two patients and mild cough in two patients
Company plans to conduct a Phase 2b multi-dose, subcutaneously-administered,
placebo-controlled, double-blinded clinical trial to test multiple dose levels and dosing
frequencies of etokimab in 300-400 eosinophilic asthma patients
18ECLIPSE: Etokimab CRSwNP Phase 2 Trial
Top-Line Data Anticipated in H2 2019
Treatment Period Monitoring Period
Week 16
Week 24
Week 0
Etokimab 300mg SC Loading Dose +
Randomization
150mg SC q4w Maintenance Dose + MFNS
n=100
Etokimab 300mg SC Loading Dose +
150mg SC q8w Maintenance Dose + MFNS
Placebo + MFNS
MFNS = mometasone furoate nasal spray
Patient Adult Chronic Rhinosinusitis with Nasal Polyps
Population Baseline NPS ≥5 and SNOT-22 >7
Key Endpoints Primary: change in NPS relative to baseline
Week 16 Primary: change in SNOT-22 relative to baseline
ClinicalTrials.gov: NCT03614923
19Wholly-Owned Pipeline: Anti-IL-36R (ANB019) Adult Generalized Pustular Psoriasis Adult Palmoplantar Pustulosis
IL-36 Dysfunction Mediates Severe Inflammatory Disease
Genetic Association with Generalized Pustular Psoriasis
Normal Individuals Disease Patients Treated Patients
Uncontrolled signaling due to dysfunctional
IL-36 cytokine signaling balanced by Anti-IL-36R antibody has the potential to
IL-36 receptor antagonist or elevated IL-36
function IL-36 receptor antagonist dampen disease by blocking the IL-36 receptor
cytokine levels
Balanced Generalized Pustular Psoriasis or Dampened
Inflammatory Response Palmoplantar Pustulosis Inflammatory Response
21Generalized Pustular Psoriasis (GPP)
Orphan Disease Associated with IL-36 Receptor Antagonist Mutations
• GPP is a systemic, life-threatening
inflammatory disease characterized by
widespread pustules
- Patients have a high fever and elevated levels of
serum CRP and inflammatory cytokines (e.g. IL-8)
• Severe GPP patients can die from
cardio-pulmonary failure, exhaustion,
toxicity and infection
- No approved therapies for treatment of GPP
• Affects approximately 3,000 patients in
the United States
22Palmoplantar Pustulosis (PPP)
Orphan Disease Associated With Elevated IL-36 Cytokine Levels
• Severe inflammation of hands
and feet
– Significant pain and inability to stand,
walk or work
• No approved therapeutic options
in this indication
• PPP is an orphan disease that
affects approximately 150,000
patients in the United States
23ANB019 Phase I Healthy Volunteer Clinical Trial
Favorable Safety, Pharmacokinetic and Pharmacodynamic Profile
• 72 healthy volunteers dosed in single ascending dose (SAD) and multiple ascending dose
(MAD) cohorts
- 36 dosed with a single subcutaneous or intravenous ANB019 doses ranging between 10mg to 750mg
- 18 dosed with 4 weekly intravenous ANB019 doses ranging between 40mg to 300mg
- 18 dosed with placebo across SAD and MAD cohorts
• Safety
- No dose limiting toxicities or serious adverse events observed
- Most frequent adverse events in SAD cohorts were upper respiratory tract infections in 10 of 36 (28%) subjects
dosed with ANB019 versus 6 of 12 (50%) subjects dosed with placebo, and headache in 10 of 36 (28%)
subjects dosed with ANB019 versus 3 of 12 (25%) subjects dosed with placebo
- In MAD cohorts, most frequent adverse event was headache in seven of 18 (39%) subjects dosed with
ANB019 versus one of six (17%) subjects dosed with placebo
• Pharmacokinetics
- Half-life of 28 days, similar between subcutaneous and intravenous route of administration
• Pharmacodynamics
- Complete inhibition of ex vivo IL-36 cytokine stimulus for 85 days post-single dose of ANB019 at certain dose
levels
Phase 1 data supports advancement into patient studies
24GALLOP: ANB019 Generalized Pustular Psoriasis Phase 2 Trial
Top-Line Data Anticipated Mid 2019
Treatment Period Monitoring Period
Week 16
Week 24
Week 0
Screening
ANB019 750mg IV Loading Dose
n=10
+ 100mg SC q4w Maintenance Dose
Patient Adult Generalized Pustular Psoriasis Patients
Population Baseline JDA Score ≥7
Key Endpoints JDA Severity Score Improvement
Week 4 & 16 Safety
25POPLAR: ANB019 Palmoplantar Pustulosis Phase 2 Trial
Top-Line Data Anticipated H1 2020
Treatment Period Monitoring Period
Week 16
Week 24
Week 0
Randomization
ANB019 200mg SC Loading Dose +
100mg SC q4w Maintenance Dose
n=50
Placebo
Patient
Adult Moderate-to-Severe Palmoplantar Pustulosis
Population
Key Endpoints PPPASI Score Improvement
Week 16 Safety
26Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030) Inflammatory Diseases
ANB030: PD-1 Agonist Antibody
Novel Anti-Inflammatory Mechanism Through Inhibitory Checkpoint Receptor
• PD-1 is a key inhibitory immune Increase T cell
activity for
checkpoint receptor responsible for PD-1 antagonist immuno-oncology
down-regulating T-cell mediated immune antibodies block
PD-1 signaling
responses Compensate for
high PD-L1
• Insufficient PD-1 signaling is associated expression by
with human inflammatory diseases Activated T Cell tumor cells
- Genetic mutations in the PD-1 pathway can
increase susceptibility to various
inflammatory conditions*
• We hypothesize that augmenting PD-1 PD-1
signaling through ANB030 treatment has
the potential to suppress human
inflammatory diseases
Compensate for
- Designed to down-regulate autoreactive T low PD-L1
PD-1 agonist
cells by mimicking the function of PD-L1 antibodies increase expression
• We anticipate filing an ANB030 IND in PD-1 signaling
Decrease T cell
H2 2019 activity to treat
inflammatory
diseases
* Okazaki and Honjo. Intern Immunol. 2007.
28ANB030: PD-1 Agonist Antibody
Augments PD-1 Signaling To Suppress Inflammatory Diseases
Activated T Cell Antigen Presenting Cell
Antigen
TCR MHC Activated T cells are down-
Healthy regulated by PD-1 mediated
negative signaling, leading to
Individuals controlled immune responses in
Negative Signal PD-1 PD-L1 healthy individuals
Insufficient negative signaling,
which could occur due to low PD-L1
Inflammatory expression, leads to excess T cell
Disease Patients activity and inflammatory diseases
Insufficient Signal PD-1 Low
PD-L1
Anticipated Effect ANB030 mimics the function of
PD-L1, restoring PD-1-mediated
of ANB030 In negative signaling on activated T
Inflammatory cells, and has the potential to
suppresses human inflammatory
Disease Patients Negative Signal diseases
ANB030
29ANB030: Generated Using AnaptysBio’s Technology Platform
Challenging Antibody Profile; Key Preclinical Properties De-Risked
ANB030 Property Preclinical Profile
• AnaptysBio’s somatic
hypermutation platform is Binding potency to Picomolar KD,
uniquely positioned to human PD-1 ~10,000x stronger than PD-L1
discover novel therapeutic
antibodies In Vitro Functional
>100x more potent IC50 than PD-L1
Activity
• PD-1 agonist antibodies are
challenging to discover due to Binding epitope Does not block PD-1 binding to PD-L1
the unique binding properties
required to augment signaling
through checkpoint receptors Demonstrated in xenogeneic
In Vivo Efficacy
mouse model of graft-versus-host disease
• ANB030 has been preclinically
High expression, stable at high
de-risked for key Manufacturability
concentrations
pharmacological and
manufacturability properties
Non-Human Primate Robust half-life and subcutaneous
Pharmacology bioavailability
30Proprietary Technology Platform
Somatic Hypermutation (SHM) Platform
Proprietary Platform Incorporates in vitro SHM and Iterative Antibody Evolution
In Vitro SHM Iterative Antibody Evolution
In vitro SHM permits access to biological targets that have been difficult
to address with prior antibody technologies
32Somatic Hypermutation (SHM) Platform
Advantages Over Competing Antibody Technologies
• Unprecedented antibody diversity through SHM
– In situ antibody diversity generation outside of the constraints of an in vivo environment
• High potency & functional activity
– Only small doses may be required to convey therapeutic effect in vivo
• Reliable manufacturability
– Increased probability of successful clinical and commercial manufacturing
• Speed: ~2.5 years from novel target to IND (or equivalent) filing
– Enables rapid development of potentially first-in-class therapeutic antibodies to emerging
target biology
33Successful Partnership Track-Record
Received ~$80MM in Cash from Partnerships Through March 31st 2019
• 3 mono-specific and 1 bi-specific programs under
TESARO development
Immuno-Oncology • Potential milestone payments of ~$1.1 billion
Partnership
• Tiered single-digit royalties
• 2 programs under development
Celgene
Inflammation • Potential milestone payments of ~$106 million
Partnership
• Single-digit royalties
34Summary
Anticipated Milestones
Multiple Additional Efficacy Readouts Anticipated From Wholly-Owned Pipeline
Program Milestone Timing
Moderate-to-Severe Adult Top-line data announced October 2017
Atopic Dermatitis Phase 2a Trial Detailed data presented at AAD and EAACI 2018
ATLAS: Moderate-to-Severe Adult
Top-line data anticipated in H2 2019
Atopic Dermatitis Phase 2b Trial
Etokimab Severe Adult Eosinophilic Top-line data presented September 2018
(anti-IL-33) Asthma Phase 2a Trial Detailed data presented at EAACI 2019
Moderate-to-Severe Eosinophilic
To be initiated in 2019
Asthma Phase 2b Trial
ECLIPSE: Adult Chronic Rhinosinusitis with
Top-line data anticipated in H2 2019
Nasal Polyps Phase 2 Trial
Top-line data announced November 2017
Healthy Volunteer Top-line Phase I Trial
Detailed data presented at EAACI 2018
ANB019
(anti-IL-36R) GALLOP: GPP Phase 2 Trial Top-line data anticipated in mid 2019
POPLAR: PPP Phase 2 Trial Top-line data anticipated in H1 2020
ANB030
IND Filing H2 2019
(anti-PD-1 Agonist)
Cash, cash equivalents and investments of approximately $484MM as of March 31st 2019
36AnaptysBio: Clinical-Stage Antibody Development Company
Focused on Novel Antibody Medicines for Severe Inflammatory Diseases
Wholly-Owned Rapid Antibody Generation
Anti-Inflammatory Pipeline Platform Technology
Etokimab (ANB020, Anti-IL-33)
Atopic Dermatitis, Eosinophilic Asthma & Chronic Rhinosinusitis with Nasal Polyps Antibody Preclinical & IND or
Discovery Translational Equivalent Filing
ANB019 (Anti-IL-36R)
Generalized Pustular Psoriasis & Palmoplantar Pustulosis
~2.5 years
ANB030 (PD-1 Agonist)
Inflammatory Diseases
Antibody Medicines
For Severe Diseases
Multiple Efficacy Readouts Anticipated
Validating Product Partnerships From Wholly-Owned Pipeline
Generated ~$80MM*
ANB019 Generalized Pustular Psoriasis Phase 2: Top-line data
in mid 2019
TESARO Etokimab Atopic Dermatitis Phase 2b: Top-line data in H2 2019
Etokimab Chronic Rhinosinusitis With Nasal Polyps Phase 2:
Celgene Top-line data in H2 2019
ANB019 Palmoplantar Pustulosis Phase 2: Top-line data in H1
2020
* As of March 31st 2019
37You can also read
